Clinical

Vyleesi™ approved to treat HSDD in premenopausal women

Vyleesi (bremelanotide) is considered a sexual dysfunction drug and is the first specialty drug in this category. It is the second drug approved by the U.S. Food and Drug Administration (FDA) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Read more

Cigna’s gaps in care program now even stronger, at no additional cost to clients

As a result of our combination with Express Scripts, Cigna has strengthened our existing gaps in care solution, Well Informed Gaps in Care, by also offering RationalMed® for Cigna. It is a way to help improve the health and safety of our members as well as drive further affordability for our clients.

Read more

Help for opioid users thanks to utilization management tactics

Cigna is committed to the fight against opioid misuse and overdose. We have set a goal to reduce overdoses among our commercial customers in key markets by 25% by December 2021.1 Our combination with Express Scripts helps strengthen our work to meet this goal.

  1. Initial focus will be on the following targeted U.S. communities where a sizable number of Cigna commercial customers reside and where there are higher incidences of overdose. These include: Connecticut, Maryland, New Jersey, Virginia, Chicago, New York City, Philadelphia, Washington, DC.

Read more

Dedicated to making insulin more affordable and accessible – Cigna’s Patient Assurance ProgramSM

For those who live with diabetes, the costs of essential medications, like insulin, shouldn’t add to their burden. That’s why Cigna will offer the Patient Assurance Program beginning in 2020. This program will assist customers with diabetes, in participating plans, to manage their costs for eligible insulin products.

Read more

New treatment for infants with spinal muscular atrophy

On May 24, 2019, the U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec), a new gene replacement therapy. Zolgensma is approved to treat children less than two years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene, a leading genetic cause of infant mortality.3

  1. Zolgensma Prescribing Information. May 2019. <https://www.avexis.com/content/pdf/prescribing_information.pdf.>

Read more

Stronger utilization management to help improve savings, quality and care

At Cigna, we use insights from our connected benefits, vast clinical expertise, and strength from our combination with Express Scripts to design comprehensive utilization management (UM) solutions that help improve outcomes and reduce costs.

“Express Scripts” is a trademark of Express Scripts Strategic Development, Inc.

Read more

Lyrica loses patent protection, generics now available

Lyrica is commonly used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, fibromyalgia or spinal cord injury. It is also used with other medications to treat certain types of seizures.2

  1. Lyrica. WebMD.com. August 5, 2019. https://www.webmd.com/drugs/2/drug-93965/lyrica-oral/details

Read more

Enhanced support with Cigna Collaborative Care® Aligned Pharmacist Program

Our Cigna Collaborative Care (CCC) Aligned Pharmacist Program aligns a pharmacist to a CCC point of contact – who may be an embedded care coordinator, a pharmacist or a quality metric person – with the goal of providing pharmacists with consistent, ongoing, personalized support.

Read more

Continuous Glucose Monitors now easier to access for less

As of April 1, 2019, Cigna will expand coverage to include pharmacy as well a medical benefits for customers managing diabetes with therapeutic Continuous Glucose Monitor (CGM) sensors. This includes Dexcom G6® and Abbott FreeStyle Libre, the only therapeutic CGMs currently on the market.

Read more

Enhanced Narcotic Therapy Management Program working to identify opioid risks

In March 2018, Cigna reached its goal of reducing opioid use by 25% among our commercial customer base – one year ahead of schedule. But our work will continue, as we work toward another milestone in reducing overdose among members.

Read more

Entresto PA removal tied to Cigna’s formulary strategy

As of November 15, 2018, Cigna has removed the prior authorization (PA) requirement for Entresto, a drug used to reduce the risk of cardiovascular death and hospitalizations for patients with chronic heart failure.

Read more

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Health benefit plans vary, but in general to be eligible for coverage a drug must be approved by the Food and Drug Administration (FDA), prescribed by a health care professional, purchased from a licensed pharmacy and medically necessary. Some plans require you to use an in-network pharmacy for prescriptions to be covered. Coverage is subject to any plan deductible, copayment and/or coinsurance requirements. Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, contact a Cigna representative. Group medical and pharmacy plans are insured and/or administered by Cigna Health and Life Insurance Company or its affiliates. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. All pictures are used for illustrative purposes only. This website is not intended for residents of New Mexico.

© 2020 Cigna. All rights reserved